The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women

Thomas J Smith, Bruce E. Hillner

Research output: Contribution to journalArticle

Abstract

Purpose and Methods: We used decision analysis to model the natural history of breast cancer in hypothetical cohorts of 45-year-old women receiving tamoxifen, chemotherapy, or combined therapy. We used recurrence and efficacy data from the Early Breast Cancer Trialists' Collaborative Group (EBCTCG), utility values from focus groups, and costs from clinic charges and Medicare data. Results: Tamoxifen alone provides minimal benefit in estrogen receptor-negative (ER- ; 0.2 to 0.4 months) and modest benefit in receptor-positive (ER+ ; 3.5 to 5.2 months) cancer. Chemotherapy adds substantial benefit independent of receptor status (4.9 to 10.7 quality-adjusted months). In ER+ cancer, combined therapy adds an additional benefit (1.2 to 2.1 months) compared with chemotherapy alone. The incremental costs (United States dollars) necessary to add an additional year of life to the average woman ranged from $4,300 to $11,400 for tamoxifen alone for ER+ cancer, $4,900 to $11,400 for chemotherapy alone, and $14,800 to $33,100 for combined therapy. Conclusion: In premenopausal early-stage breast cancer, chemotherapy adds substantial clinical benefit at a modest cost. Tamoxifen alone adds meaningful benefit only in ER+ cancer. Combined therapy is effective for all women, but is most beneficial and only cost-effective in ER+ women. If secondary effects of tamoxifen in reduction of cardiovascular and osteoporosis mortality are confirmed, then combined treatment may be optimal for all premenopausal women.

Original languageEnglish (US)
Pages (from-to)771-776
Number of pages6
JournalJournal of Clinical Oncology
Volume11
Issue number4
StatePublished - 1993
Externally publishedYes

Fingerprint

Tamoxifen
Cost-Benefit Analysis
Breast Neoplasms
Drug Therapy
Costs and Cost Analysis
Neoplasms
Therapeutics
Decision Support Techniques
Medicare
Focus Groups
Estrogen Receptors
Osteoporosis
Recurrence
Mortality

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women. / Smith, Thomas J; Hillner, Bruce E.

In: Journal of Clinical Oncology, Vol. 11, No. 4, 1993, p. 771-776.

Research output: Contribution to journalArticle

@article{e6db5a9e1eec4f6eab02837e98d853e1,
title = "The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women",
abstract = "Purpose and Methods: We used decision analysis to model the natural history of breast cancer in hypothetical cohorts of 45-year-old women receiving tamoxifen, chemotherapy, or combined therapy. We used recurrence and efficacy data from the Early Breast Cancer Trialists' Collaborative Group (EBCTCG), utility values from focus groups, and costs from clinic charges and Medicare data. Results: Tamoxifen alone provides minimal benefit in estrogen receptor-negative (ER- ; 0.2 to 0.4 months) and modest benefit in receptor-positive (ER+ ; 3.5 to 5.2 months) cancer. Chemotherapy adds substantial benefit independent of receptor status (4.9 to 10.7 quality-adjusted months). In ER+ cancer, combined therapy adds an additional benefit (1.2 to 2.1 months) compared with chemotherapy alone. The incremental costs (United States dollars) necessary to add an additional year of life to the average woman ranged from $4,300 to $11,400 for tamoxifen alone for ER+ cancer, $4,900 to $11,400 for chemotherapy alone, and $14,800 to $33,100 for combined therapy. Conclusion: In premenopausal early-stage breast cancer, chemotherapy adds substantial clinical benefit at a modest cost. Tamoxifen alone adds meaningful benefit only in ER+ cancer. Combined therapy is effective for all women, but is most beneficial and only cost-effective in ER+ women. If secondary effects of tamoxifen in reduction of cardiovascular and osteoporosis mortality are confirmed, then combined treatment may be optimal for all premenopausal women.",
author = "Smith, {Thomas J} and Hillner, {Bruce E.}",
year = "1993",
language = "English (US)",
volume = "11",
pages = "771--776",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "4",

}

TY - JOUR

T1 - The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women

AU - Smith, Thomas J

AU - Hillner, Bruce E.

PY - 1993

Y1 - 1993

N2 - Purpose and Methods: We used decision analysis to model the natural history of breast cancer in hypothetical cohorts of 45-year-old women receiving tamoxifen, chemotherapy, or combined therapy. We used recurrence and efficacy data from the Early Breast Cancer Trialists' Collaborative Group (EBCTCG), utility values from focus groups, and costs from clinic charges and Medicare data. Results: Tamoxifen alone provides minimal benefit in estrogen receptor-negative (ER- ; 0.2 to 0.4 months) and modest benefit in receptor-positive (ER+ ; 3.5 to 5.2 months) cancer. Chemotherapy adds substantial benefit independent of receptor status (4.9 to 10.7 quality-adjusted months). In ER+ cancer, combined therapy adds an additional benefit (1.2 to 2.1 months) compared with chemotherapy alone. The incremental costs (United States dollars) necessary to add an additional year of life to the average woman ranged from $4,300 to $11,400 for tamoxifen alone for ER+ cancer, $4,900 to $11,400 for chemotherapy alone, and $14,800 to $33,100 for combined therapy. Conclusion: In premenopausal early-stage breast cancer, chemotherapy adds substantial clinical benefit at a modest cost. Tamoxifen alone adds meaningful benefit only in ER+ cancer. Combined therapy is effective for all women, but is most beneficial and only cost-effective in ER+ women. If secondary effects of tamoxifen in reduction of cardiovascular and osteoporosis mortality are confirmed, then combined treatment may be optimal for all premenopausal women.

AB - Purpose and Methods: We used decision analysis to model the natural history of breast cancer in hypothetical cohorts of 45-year-old women receiving tamoxifen, chemotherapy, or combined therapy. We used recurrence and efficacy data from the Early Breast Cancer Trialists' Collaborative Group (EBCTCG), utility values from focus groups, and costs from clinic charges and Medicare data. Results: Tamoxifen alone provides minimal benefit in estrogen receptor-negative (ER- ; 0.2 to 0.4 months) and modest benefit in receptor-positive (ER+ ; 3.5 to 5.2 months) cancer. Chemotherapy adds substantial benefit independent of receptor status (4.9 to 10.7 quality-adjusted months). In ER+ cancer, combined therapy adds an additional benefit (1.2 to 2.1 months) compared with chemotherapy alone. The incremental costs (United States dollars) necessary to add an additional year of life to the average woman ranged from $4,300 to $11,400 for tamoxifen alone for ER+ cancer, $4,900 to $11,400 for chemotherapy alone, and $14,800 to $33,100 for combined therapy. Conclusion: In premenopausal early-stage breast cancer, chemotherapy adds substantial clinical benefit at a modest cost. Tamoxifen alone adds meaningful benefit only in ER+ cancer. Combined therapy is effective for all women, but is most beneficial and only cost-effective in ER+ women. If secondary effects of tamoxifen in reduction of cardiovascular and osteoporosis mortality are confirmed, then combined treatment may be optimal for all premenopausal women.

UR - http://www.scopus.com/inward/record.url?scp=0027400930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027400930&partnerID=8YFLogxK

M3 - Article

C2 - 8478670

AN - SCOPUS:0027400930

VL - 11

SP - 771

EP - 776

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 4

ER -